Sara M. Tolaney, MD, MPH, reflects on a patient from her fellowship who presented with an extensive HER2-positive inflammatory breast cancer. Despite initial concerns about her long-term outcomes, the patient achieved a pathologic complete response after receiving preoperative chemotherapy with ACTH and trastuzumab.
Dr Tolaney notes that this experience highlights the advancements that have allowed for a deeper understanding of individual tumor biology and the development of new therapeutics that can effectively target drivers of breast cancer growth, leading to the potential for early-stage breast cancer to be cured in many cases.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Reflections on a Patient With HER2-Positive Inflammatory Breast Cancer - Medscape - Apr 24, 2023.
Comments